Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
Description: Arrowhead Research Corporation develops novel drugs to treat intractable diseases in the United States. The company?s principal product candidates comprise ARC-520, an RNAi-based therapeutic that is in Phase IIa clinical trial to treat chronic hepatitis B virus infection; and ARC-AAT, a novel unlocked nucleobase analog containing RNAi-based therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. Its platform technology include Dynamic Polyconjugate platform, an RNAi delivery system that addresses multiple organ systems and cell types. The company is also involved in the development of Adipotide, which is in phase I clinical trial for the treatment of obesity and metabolic disorders; and CRLX-101 that is in phase II clinical trial to treat various cancer types, including relapsed renal cell carcinoma, relapsed ovarian cancer, and non-metastatic rectal cancer. It has research collaboration and license agreement with Shire AG to develop and commercialize targeted peptide-dr
|Shares Outstanding||EPS||-0.89||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||0%||Sales Growth - Q/Q||-74.27%||P/E||-1.79|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-52.54%||ROE||-59.17%||ROI||-56.98%|
|Current Ratio||9.1||Quick Ratio||Long Term Debt/Equity||0.01||Debt Ratio||0.09|
|Gross Margin||Operating Margin||-29638.3%||Net Profit Margin||-28158.4%||Dividend Payout Ratio|
|Cash From Financing Activities||210 K||Cash From Investing Activities||4.3 M||Cash From Operating Activities||-40.57 M||Gross Profit|
|Net Profit||-28.68 M||Operating Profit||-29.63 M||Total Assets||162.38 M||Total Current Assets||120.15 M|
|Total Current Liabilities||13.21 M||Total Debt||870 K||Total Liabilities||17.63 M||Total Revenue||40 K|
|High 52 week||29.98||Low 52 week||10.74||Last close||29.05||Last change||-0.31%|
|RSI||44.77||Average true range||1.24||Beta||0.59||Volume||4.6 M|
|Simple moving average 20 days||0.31%||Simple moving average 50 days||5.31%||Simple moving average 200 days||51.5%|
|Performance Week||-0.24%||Performance Month||10.5%||Performance Quart||48.9%||Performance Half||85.5%|
|Performance Year||80.21%||Performance Year-to-date||133.9%||Volatility daily||2.62%||Volatility weekly||5.86%|
|Volatility monthly||12.01%||Volatility yearly||41.59%||Relative Volume||448.74%||Average Volume||2.07 M|
|New High||New Low|
2020-02-07 09:36:02 | Should First Trust Mid Cap Growth AlphaDEX ETF FNY Be on Your Investing Radar?
2020-02-06 01:17:16 | Edited Transcript of ARWR earnings conference call or presentation 5-Feb-20 9:30pm GMT
2020-02-05 16:00:00 | Arrowhead Pharmaceuticals Reports Fiscal 2020 First Quarter Results
2020-02-03 13:06:06 | Arrowhead ARWR to Report Q1 Earnings: What's in the Cards?
2020-01-24 05:31:35 | Is Arrowhead Pharmaceuticals, Inc. NASDAQ:ARWR A Volatile Stock?
2020-01-22 16:29:54 | Will These Biotechs Rival A Top-Notch Stock In High Triglycerides?
2020-01-22 07:30:00 | Arrowhead Pharmaceuticals to Webcast Fiscal 2020 First Quarter Results
2020-01-21 16:30:06 | Why This Top-Notch Biotech Stock Just Plunged By Double Digits
2020-01-11 08:00:55 | Vertex, Dexcom, Insulet, Intuitive Surgical In Buy Range Before Healthcare Conference
2020-01-11 08:00:55 | These Four Stocks Are In Buy Range Before Key Healthcare Conference
2020-01-10 11:51:43 | 3 Biotech Stocks to Bank on for Buyouts in 2020
2020-01-06 07:30:00 | Arrowhead Pharmaceuticals Appoints James Hassard as Chief Commercial Officer
2020-01-02 08:00:28 | Biotech Stocks Are On Fire — Who's Leading The Profit Pack For 2020?
2019-12-27 18:06:44 | Best Stocks 2019: Innovation, As Usual, Wins The Day — Or Even The Year
2019-12-26 05:27:10 | Should First Trust Mid Cap Growth AlphaDEX Fund FNY Be on Your Investing Radar?
2019-12-24 10:00:00 | What was the top stock of 2019? And should it be in your retirement account?
2019-12-23 10:21:00 | Arrowhead Pharma Investors Should Aim for Taking Profits
2019-12-23 08:00:01 | Should You Invest in the Invesco S&P SmallCap Health Care ETF PSCH?
2019-12-16 16:15:00 | Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635c4
2019-12-13 07:30:00 | Arrowhead Pharmaceuticals Appoints Marianne De Backer to Board of Directors
2019-12-11 15:46:48 | Did Hedge Funds Drop The Ball On Arrowhead Research Corp ARWR ?
2019-12-03 09:26:27 | Where to Buy Booming Biotech ETFs
2019-12-03 06:55:11 | Should First Trust Mid Cap Growth AlphaDEX Fund FNY Be on Your Investing Radar?
2019-12-02 16:48:39 | This Highly Rated Biotech Company Just Tumbled 13% On A Public Offering
2019-12-02 16:05:00 | Arrowhead Pharmaceuticals Announces Proposed Underwritten Offering of Common Stock
2019-12-02 14:57:21 | 7 Exciting Biotech Stocks to Buy Now
2019-11-29 13:23:14 | This Biotech With 488% Growth In 2019 Just Gained A Price-Target Boost
2019-11-29 09:52:00 | Biotech Arrowhead Stock’s Surge Will Continue, Analyst Says
2019-11-28 08:07:01 | Should You Invest in the Invesco S&P SmallCap Health Care ETF PSCH?
2019-11-26 16:00:00 | Arrowhead Pharmaceuticals to Participate in Upcoming December 2019 Conferences
2019-11-26 03:33:22 | Edited Transcript of ARWR earnings conference call or presentation 25-Nov-19 9:30pm GMT
2019-11-25 16:00:00 | Arrowhead Pharmaceuticals Reports Fiscal Year 2019 Results
2019-11-25 10:27:00 | Novartis’s Deal for Medicines Company Is Good News for 2 More Stocks
2019-11-15 07:30:00 | Arrowhead Pharmaceuticals Announces Planned Management Transition
2019-11-13 14:12:11 | Arrowhead Shares Are Still Alerting Big Buy Signals
2019-11-11 07:30:00 | Arrowhead Pharmaceuticals to Webcast Fiscal 2019 Year End Results